Phase 1 or 2 clinical trials have been designed to evaluate the tolerability and efficacy of a CCR2/5 dual inhibitor, BMS-813160, together with nivolumab, gemcitabine, and nab-paclitaxel in patients with borderline resectable and locally advanced PDAC (NCT03496662) or with/without GVAX (a GM-CSF gene-transfected tumor cell vaccine) following chemotherapy and radiotherapy in patients with locally advanced PDAC (NCT03767582). The gene discussed is CSF2; the disease is neoplasm.